



cells



an Open Access Journal by MDPI

CAR T-cell Immunotherapy-the Living Drugs for Lethal Diseases

Guest Editors:

Dr. Antonio Pérez Martínez

Department of Pediatrics,
University Hospital La Paz,
Universidad Autónoma de
Madrid, Paseo de la Castellana
261, 28046 Madrid, Spain

Dr. Patrick Schlegel

Abteilung I
(Hämatologie/Onkologie),
Universitätsklinik für Kinder- und
Jugendmedizin, Hoppe-Seyler-
Straße 1, 72076 Tübingen,
Germany

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Dear Colleagues,

Chimeric Antigen Receptor (CAR) expressed in autologous T cells targeting B-lymphocyte antigen CD19 has been successful scaled to clinical setting for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and diffuse B cell lymphoma (DBCL). Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta) have been the first “living drugs”. However, other CAR expressed on different effector cells targeting tumor specific antigens are being faster developed for other malignancies and catastrophic diseases. In this current perspective, it has revalued the immunotherapy as a hopeful treatment based on specific cell recognition and activation. The aim of this Special Issue is to provide an overview of the CAR cell field biology from the basic and translational development to the manufacturing and clinical impact and future challenges. We hope that the reports presented by basic and clinical researchers will be a valuable for continuous improvement for the community of researchers and physicians investigating on CAR cells in different diseases and aims and objectives.

Dr. Antonio Pérez Martínez

Dr. Patrick Schlegel

Guest Editors



mdpi.com/si/60052

Special Issue



cells



an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities,
6-145 Jackson Hall, 321 Church St
SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation
Centre, The University of
Copenhagen, Copenhagen,
Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (*General Biochemistry, Genetics and Molecular Biology*)

Contact Us

Cells Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cells
cells@mdpi.com
[X@Cells_MDPI](https://twitter.com/Cells_MDPI)